{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nevi+and+Melanomas&page=2", "query": { "condition": "Nevi and Melanomas", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nevi+and+Melanomas&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T17:06:38.640Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00450372", "title": "Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "ADI-PEG-20", "type": "BIOLOGICAL" }, { "name": "Pharmacology Studies", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 38, "start_date": "2004-06", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2017-02-08", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450372" }, { "nct_id": "NCT03993379", "title": "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Unresectable or Metastatic Melanoma" ], "interventions": [ { "name": "CX-072", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytomX Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-11-20", "completion_date": "2020-05-21", "has_results": true, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03993379" }, { "nct_id": "NCT05061134", "title": "A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 194, "start_date": "2022-08-11", "completion_date": "2026-11-02", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 6, "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Lutherville-Timonium", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05061134" }, { "nct_id": "NCT00862901", "title": "Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Skin Cancer" ], "interventions": [ { "name": "CLIPT patch", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2009-01", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2011-09-26", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00862901" }, { "nct_id": "NCT00327600", "title": "Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "imexon", "type": "DRUG" }, { "name": "DTIC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AmpliMed Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 68, "start_date": "2005-07", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2010-09-15", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 11, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00327600" }, { "nct_id": "NCT02743611", "title": "Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Uveal Melanoma" ], "interventions": [ { "name": "BPX-701", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2017-04-14", "completion_date": "2020-07-19", "has_results": true, "last_update_posted_date": "2023-10-05", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 3, "location_summary": "Denver, Colorado • Portland, Oregon • Nashville, Tennessee", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02743611" }, { "nct_id": "NCT02306512", "title": "Mohs and Immunofluorescence for Malignant Melanoma In Situ", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lentigo Maligna", "Melanoma In Situ" ], "interventions": [ { "name": "H&E", "type": "PROCEDURE" }, { "name": "IHC MART-1", "type": "PROCEDURE" }, { "name": "IF MART-1", "type": "PROCEDURE" }, { "name": "IF cocktail", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-06", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2019-01-07", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 2, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02306512" }, { "nct_id": "NCT00079144", "title": "Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "NY-ESO-1 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2004-01", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079144" }, { "nct_id": "NCT02423863", "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Head and Neck Cancer", "Sarcoma", "Non-Melanoma Skin Cancers" ], "interventions": [ { "name": "Hiltonol", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oncovir, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2015-03", "completion_date": "2020-08-31", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 5, "location_summary": "Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more", "locations": [ { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Easton", "state": "Maryland" }, { "city": "Columbia", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02423863" }, { "nct_id": "NCT00706992", "title": "Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "ALVAC-MART-1 vaccine", "type": "BIOLOGICAL" }, { "name": "MART-1:26-35(27L) peptide vaccine", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2008-06", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-07-24T17:06:38.640Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00706992" } ] }